Detalhe da pesquisa
1.
Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I study.
Invest New Drugs
; 39(5): 1298-1305, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33738668
2.
Vorolanib, an oral VEGFR/PDGFR dual tyrosine kinase inhibitor for treatment of patients with advanced solid tumors: An open-label, phase I dose escalation and dose expansion trial.
Chin J Cancer Res
; 33(1): 103-114, 2021 Feb 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-33707933
3.
Phase I, First-in-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Vorolanib in Patients with Advanced Solid Tumors.
Oncologist
; 24(4): 455-e121, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30478190
4.
Dual PI3 K/mTOR inhibition reduces prostate cancer bone engraftment altering tumor-induced bone remodeling.
Tumour Biol
; 40(4): 1010428318771773, 2018 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-29687745
5.
Safety and tolerability of oral vorolanib for neovascular (wet) age-related macular degeneration: a phase I, open-label study.
Eye (Lond)
; 37(15): 3228-3233, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37041349
6.
Vorolanib, a novel tyrosine receptor kinase receptor inhibitor with potent preclinical anti-angiogenic and anti-tumor activity.
Mol Ther Oncolytics
; 24: 577-584, 2022 Mar 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-35252556
7.
Phase 1b trial of anti-VEGF/PDGFR vorolanib combined with immune checkpoint inhibitors in patients with advanced solid tumors.
Cancer Chemother Pharmacol
; 89(4): 487-497, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35247086
8.
Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial.
JAMA Oncol
; 7(11): 1617-1625, 2021 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34473194
9.
Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung Cancer.
J Thorac Oncol
; 14(11): 1901-1911, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31446141
10.
Pharmacodynamic study using FLT PET/CT in advanced solid malignancies treated with a sequential combination of X-82 and docetaxel.
Cancer Chemother Pharmacol
; 82(2): 211-219, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29802443
11.
Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study.
Clin Cancer Res
; 24(12): 2771-2779, 2018 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29563138
12.
SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity.
Mol Cancer Ther
; 5(7): 1774-82, 2006 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-16891463
13.
Oral Tyrosine Kinase Inhibitor for Neovascular Age-Related Macular Degeneration: A Phase 1 Dose-Escalation Study.
JAMA Ophthalmol
; 135(7): 761-767, 2017 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28570723
14.
New therapeutic strategies in neuroblastoma: combined targeting of a novel tyrosine kinase inhibitor and liposomal siRNAs against ALK.
Oncotarget
; 6(30): 28774-89, 2015 Oct 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-26299615
15.
Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment.
Clin Cancer Res
; 21(14): 3327-39, 2015 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25805801
16.
Derivation of class II force fields. VIII. Derivation of a general quantum mechanical force field for organic compounds.
J Comput Chem
; 22(15): 1782-1800, 2001 Nov 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-12116411
17.
Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase.
J Med Chem
; 46(7): 1116-9, 2003 Mar 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-12646019
18.
Simultaneous targeting of PI3Kδ and a PI3Kδ-dependent MEK1/2-Erk1/2 pathway for therapy in pediatric B-cell acute lymphoblastic leukemia.
Oncotarget
; 5(21): 10732-44, 2014 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25313141
19.
A novel lead compound CM-118: antitumor activity and new insight into the molecular mechanism and combination therapy strategy in c-Met- and ALK-dependent cancers.
Cancer Biol Ther
; 15(6): 721-34, 2014 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24618813
20.
Inhibition of tumor cell growth, proliferation and migration by X-387, a novel active-site inhibitor of mTOR.
Biochem Pharmacol
; 83(9): 1183-94, 2012 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22305748